Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Next Previous
X
Search
Trial Profile

An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalzanemdor (Primary)
  • Indications Dementia; Mild cognitive impairment
  • Focus Adverse reactions
  • Acronyms LUMINARY
  • Sponsors Sage Therapeutics

    • Most Recent Events

    • 04 Aug 2022 Results reporting safety/tolerability of SAGE-718 and its effects on cognitive symptoms in patients with AD presented at the Alzheimer's Association International Conference 2022
    • 26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
    • 01 Apr 2022 According to a SAGE Therapeutics media release, data from this trial will be presented during the Emerging Science Session at the 74th Annual Meeting of the American Academy of Neurology (AAN) 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top